Title : VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.

Pub. Date : 2011 Nov 1

PMID : 21885916

1 Functional Relationships(s)
Compound Name
Protein Name
1 Importantly, we found that while both VMY and flavopiridol inhibited intracellular CDK1 catalytic activity, VMY-1-103 was unique in its ability to severely disrupt the mitotic spindle apparatus significantly delaying metaphase and disrupting mitosis. alvocidib cyclin dependent kinase 1 Homo sapiens